Targacept , Inc.  

(Public, NASDAQ:TRGT)   Watch this stock  
Find more results for TRGT
2.63
+0.05 (1.94%)
Feb 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.56 - 2.64
52 week 2.25 - 5.23
Open 2.56
Vol / Avg. 47,492.00/41,527.00
Mkt cap 88.52M
P/E     -
Div/yield     -
EPS -1.23
Shares 34.31M
Beta 1.76
Inst. own 74%
Feb 13, 2015
Q4 2014 Targacept Inc Earnings Release (Estimated)
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -19440.00% -1286.99%
Operating margin -19952.00% -1301.08%
EBITD margin - -1286.00%
Return on average assets -16.20% -27.85%
Return on average equity -16.96% -30.08%
Employees 39 -
CDP Score - -

Address

Suite 1510, 100 North Main Street
WINSTON-SALEM, NC 27101
United States - Map
+1-336-4802100 (Phone)
+1-336-4802107 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Targacept, Inc. is a biopharmaceutical company engaged in the development of novel NNR Therapeutics to treat patients suffering from serious nervous system and gastrointestinal or genitourinary diseases and disorders. The Company�s NNR Therapeutics target a class of receptors known as neuronal nicotinic receptors, which it refers to as NNRs which are found on nerve cells throughout the nervous system and serve as key regulators of nervous system activity. The Company�s product candidates include: TC-5214, which acts as an antagonist on the a3b4 NNR; TC-1734 (also referred to as AZD3480) which is a wholly owned novel small molecule that modulates the activity of the a4b2 NNR; TC-6499 which is a novel small molecule that modulates the activity of the a3b4 and other NNRs as an agonist; AZD1446 which is a novel small molecule that modulates the activity of the a4b2 NNR; and TC-5619 and TC-6987 which are novel small molecules highly selective for the a7 NNR.

Officers and directors

Stephen Anthony Hill M.D. President, Chief Executive Officer, Director
Age: 56
Bio & Compensation  - Reuters
Mauri K. Hodges CPA Chief Financial Officer, Vice President of Finance and Administration, Treasurer
Age: 54
Bio & Compensation  - Reuters
Patrick C. Rock J.D. Senior Vice President, General Counsel, Secretary
Age: 54
Bio & Compensation  - Reuters
Steven M. Toler Ph.D Vice President - Clinical Pharmaceutical Sciences
Age: 53
Bio & Compensation  - Reuters
Patrick M. Sheller General Counsel
Age: 52
Bio & Compensation  - Reuters
John P. Richard Non-Executive Independent Chairman of the Board
Age: 56
Bio & Compensation  - Reuters
Charles A. Blixt Esq. Independent Director
Age: 63
Bio & Compensation  - Reuters
Julia R. Brown Independent Director
Age: 66
Bio & Compensation  - Reuters
Errol B. De Souza Ph.D. Independent Director
Age: 60
Bio & Compensation  - Reuters